|
| Wednesday, 18 January 2017, 14:23 JST | |
| |  | |
Source: Eisai | |
|
|
|
|
| Accelerating Access to Health Care in Low and Lower-Middle Income Countries |
TOKYO, Jan 18, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it is participating in Access Accelerated, a global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries.
Access Accelerated is the first multi-stakeholder, international initiative in the field of NCDs, consisting of 22 major pharmaceutical companies, including Eisai, in collaboration with the World Bank Group and the Union for International Cancer Control (UICC). The aim of Access Accelerated is to work towards the United Nation's Sustainable Development Goal target of reducing the number of premature deaths from NCDs in low and lower-middle income countries by one-third by 2030. In addition to the individual programs to improve access to health care run by each of the participating companies, this initiative will conduct pilots for improving prevention, treatment and care of NCDs in collaboration with the World Bank Group. Furthermore, in collaboration with the UICC, this initiative will support the provision of effective, sustainable diagnosis and treatment, for the purpose of improving cancer treatment and care.
To address global NCDs issues, Eisai has been running various initiatives in each country to improve access, including an Alzheimer's disease awareness and early detection campaign in China, and the introduction of tiered pricing, an affordable pricing model for our global product anticancer agent Halaven in seven Asian countries, including India, Thailand and the Philippines, where prices are set at several levels in accordance with the income levels of patients.
With regard to Eisai's participation in Access Accelerated, CEO Haruo Naito commented "One of the missions of the modern pharmaceutical industry is to make drugs accessible to all patients, no matter their socioeconomic status. In line with its human health care (hhc) philosophy, Eisai is pleased to take part in
initiatives like Access Accelerated to help address the social and medical needs of patients and their caregivers. For Eisai, pursuing solutions for global access challenges is both our responsibility and a long-term investment into the future."
About Access Accelerated
Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving NCDs care. Involving more than 20 pharmaceutical companies, the initiative works with partners such as World Bank Group and the Union for International Cancer Control (UICC) to help overcome a variety of access barriers to NCDs medicines in low-income and lower-middle income countries. Access Accelerated will support multi-stakeholder dialogue and begin on-the-ground work to improve NCDs prevention, diagnosis and treatment.
Contributing companies include: Almirall, Astellas, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, EFPIA, GlaxoSmithKline, The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Johnson & Johnson, JPMA, Menarini, Merck KGaA, MSD, Novartis, Pfizer, PhRMA, Roche, Sanofi, Shionogi, Sumitomo Dainippon, Takeda and UCB. IFPMA will act as the Secretariat for Access Accelerated.
About Non-Communicable Diseases (NCDs)
NCDs, including cancers, cardiovascular diseases, chronic respiratory disease, diabetes and mental health disorders are the leading causes of death and disability worldwide. An estimated 80% of NCD-related deaths occur in low and lower-middle income countries, and countermeasures for NCDs have become an urgent issue.
About Eisai's initiatives for improving Access to Medicine
Eisai considers its activities for improving access to medicine in developing and emerging countries as a form of long-term investment for future growth, and is currently running various proactive, sustainable initiatives.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
| Eisai Related News |
|
| 2026年5月8日 17時00分 JST |
| エーザイとバイオジェン・インク、抗 Aβ抗体レカネマブの皮下注射製剤「LEQEMBI(R) IQLIK(TM)」の早期アルツハイマー病に対する初期療法に関する米国 FDA による優先審査の状況について |
|
| 2026年4月22日 10時40分 JST |
| エーザイとMerck & Co., Inc、進行腎細胞がん（RCC）患者様を対象とした一次治療としての併用療法を評価する臨床第III相「LITESPARK-012」試験の状況について |
|
| Tuesday, 21 April 2026, 20:52 JST |
| Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) |
|
| Friday, 27 March 2026, 20:14 JST |
| Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy |
|
| Friday, 27 March 2026, 18:19 JST |
| Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency |
|
| More news >> |
|
|
|
